Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
about
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week studyTiotropium versus ipratropium bromide for chronic obstructive pulmonary diseaseTiotropium versus ipratropium bromide for chronic obstructive pulmonary diseaseTiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary diseaseTiotropium for stable chronic obstructive pulmonary diseaseA rational approach to single, dual and triple therapy in COPDPharmacological strategies to reduce exacerbation risk in COPD: a narrative reviewThe association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysisPredicting chronic obstructive pulmonary disease hospitalizations based on concurrent influenza activityHealth-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review.COPD exacerbations. 4: PreventionTiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 updateDoes tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysisPulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.Comparing methods of data synthesis: re-estimating parameters of an existing probabilistic cost-effectiveness model.Tiotropium (Spiriva): a once-daily inhaled anticholinergic medication for chronic obstructive pulmonary diseaseInhaled anticholinergic drugs and risk of acute urinary retention.Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studiesTiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease.Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease.Association between lung function and exacerbation frequency in patients with COPD.Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary diseasePharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary diseaseMuscarinic receptor signaling in the pathophysiology of asthma and COPD.Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD.Management of an acute exacerbation of copd: are we ignoring the evidence?Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switchInformation for physicians and pharmacists about drugs that might cause dry mouth: a study of monographs and published literature.Advances in the management of chronic obstructive pulmonary disease.Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease.Chronic obstructive pulmonary disease * 12: New treatments for COPDTiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trialA bibliometric analysis of the 100 most influential papers on COPDEfficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease.Chronic obstructive pulmonary disease: the clinical management of an acute exacerbation.Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDEffect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study.
P2860
Q21257191-147C6FD9-E682-49E2-A826-FA88DFDB3393Q24187073-D1FFA92D-4ED1-42E5-88B2-051468D190BDQ24198068-BD5281DD-595E-4F86-BF35-21F722844061Q24200476-5520ACEC-6352-4D15-B932-F6A0B831BF7CQ24246991-10A48186-1C47-4177-BBC1-2026BD240721Q26776477-AF2234F1-B8A9-4A48-9A2F-B3ABEB12FD8DQ28070274-063F8AFF-5DB7-49F0-8F26-A2E9586B350FQ28070325-A1D50FD2-47CD-41D3-AA55-2C8D319FEDF8Q30432654-44C8FE10-CE59-40D1-A033-E2C35A1C44DFQ30478617-F5246090-9099-4283-B16B-D28DE6885961Q30480789-69B2BDF7-299C-469F-8FFF-B169314A0716Q30620671-04AEC278-FAF0-40F8-B020-00B4E1846074Q33591899-186BB8ED-AC77-4B63-A007-AF41F307B064Q33698524-505AA05C-F6B9-438E-B0E5-DCEA18A83225Q33711672-40261EB9-4FAE-47CE-A818-ED2BBC695A13Q33766133-24C3D1AE-FDBE-4DFA-BF73-70D0E5A38C49Q33944981-AEA61306-7B59-4C12-9367-02047FD5EA50Q34024144-D09512F5-508E-4A8F-9B34-AD80ECB543B4Q34065963-52268C59-FBBE-43A0-80D4-4DE9E9E8DEAEQ34177358-04F54A47-0106-4661-85D0-40EF115AB07FQ34243574-82208E31-6D6D-401D-B94F-DD2007149EB0Q34309072-5C5B4B63-58E7-4D01-B75B-268BC9740AC5Q34432556-1F216F7A-D934-4867-8F24-DF293DF33041Q34554784-90BD3D0E-7153-486F-B091-1AE213030B75Q34677811-B51F1FB6-9732-46AC-9F25-9B4D4F04C9C2Q34684230-2C084108-598D-4D62-9117-BBE1127F2AAAQ34903093-5B9CC84B-545A-4DEE-86CA-0C176A4E6457Q34938599-BF880CB9-394C-4931-BB6C-5AB81FAA953BQ34944616-BD4CCE00-8ED4-4389-83FA-9C99BF53FF2CQ35057288-7395E409-3786-4B3A-83CC-58110983348DQ35164693-D1975AC5-CB13-42C2-B705-14EB5C4B6EC6Q35205369-6C09D779-E990-41F7-913E-3266D7D99DE3Q35208742-0988C54B-1C5A-43E3-AB80-A76F49CF636FQ35215919-CAB2E794-EF29-4A0D-8D6E-5E89301B090BQ35230811-10BB3465-0630-41B0-BD20-41F2A35C12F9Q35350962-AAA2FA12-5AB4-41AF-8D0A-57897BCA88B8Q35508561-EAA2EFA7-BA8E-4452-8F56-F72CAB2D1077Q35520406-C4214488-12B7-41B6-98CB-58FA86D024CEQ35535912-28C118E0-9525-4E6E-A6FE-B168F6B4918FQ35536623-A9FE185A-3B23-4BB3-94DD-40A04E8E0543
P2860
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
@en
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
@nl
type
label
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
@en
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
@nl
prefLabel
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
@en
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
@nl
P2093
P1476
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
@en
P2093
A P M Greefhorst
Dutch/Belgian Tiotropium Study Group
J A van Noord
L Korducki
P J G Cornelissen
Th A Bantje
P304
P356
10.1183/09031936.02.00238702
P577
2002-02-01T00:00:00Z